Xarelto (Rivaroxaban) is an FXa inhibitor indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for extended risk reduction. Xarelto medication is mostly prescribed to the patients who were gone through hip and knee replacement surgeries. It generally is prescribed as an alternative to warfarin (Coumadin), a blood thinner that began to be used in 1954. The patients took Xarelto to treat them from atrial fibrillation (irregular heart rhythm), hypertension, or other valvular heart conditions. Though, most of the patients are not aware that this medication can cause severe side effects leading to death. The most serious potential side effects, complications and risks caused by Xarelto are severe internal bleeding, hemorrhaging and wrongful death, with no antidote available for doctors to control Xarelto bleeding events.
As of November more than 9,000 lawsuits have been filed across the country against the Manufacturers and marketers of Xarelto. The lawsuits are in process regarding Xarelto and according to the reports all the Xarelto lawsuits will be consolidated for multidistrict litigation. Currently, more than 7,000 cases are pending in New Orleans, Louisiana in the multi-district (MDL) overseen by U.S. District Court Judge Eldon Fallon. About 1,000 cases have also been filed in Pennsylvania and another 1,000 in Delaware. The most of the lawsuits were filed against its manufacturers, Janssen Pharmaceuticals and Bayer AG alleging that these companies failed to warn patients and physicians of the increased risks of fatal internal bleeding when using Xarelto. The four bellwether cases that have been selected scheduled to begin in early 2017 in Louisiana, Mississippi, and Texas; these cases could set the tone for future Xarelto lawsuits. The lawsuits are challenging the safety of Bayer AG and Johnson & Johnson subsidiary Janssen’s blockbuster blood thinner Xarelto.
Xarelto received two ‘black box’ warnings from the FDA. These warnings are the strictest warning a product can receive before being pulled completely from the market. The U.S. Food and Drug Administration reveals the data of the Institute of Safe Medication Practices which shows that Xarelto accounted for the largest number of reported cases of domestic, serious injury among regularly monitored drugs in 2015. Earlier this year, in February 2016, researchers from the Duke Institute have performed the ROCKET-AF trial, provided a new in-depth analysis of the new blood thinner’s efficacy and safety outcomes after five years of use. The test results reveal that the previous findings of Rivaroxaban superiority over Warfarin were false. The Duke researchers were hiding valuable information as they were conspirator with Bayer and J&J. According to the studies done by researchers, the drug makers may have reduced the risk of patients dying on Xarelto from uncontrollable bleeding if they had provided stronger warnings and recommended blood monitoring during treatment.
The manufacturers placed their desire for profits before consumer safety by failing to fully explore all potential reversal agents before introducing the medication. Plaintiffs from all over the nation will have to wait just a little longer for their day in court with the drug manufacturer. Bellwether trials are scheduled to begin in early 2017. Bellwether trials are used in mass tort actions when thousand of lawsuits have filed against one manufacturer and have similar allegations. The actual outcome from the judgment may be utilized for valuing groups of claims in settlements. If you or your love ones are facing fatal complication due to the blockbuster blood thinner Xarelto can take a legal action against the company. He/she can claim for reimbursement money against complication or loss within limited period of time. We have an experience attorneys group who evaluate your case free of cost unless we win the case for you. Contact Drugsclaim.com for free case review.